Although<unk>  cures about 96% of people with late stage disease, its toxicity limits its use. About 1-5% of people die during treatment. As a toxic organic compound of arsenic,<unk>  is a dangerous treatment that is typically only administered by injection under the supervision of a licensed physician. Notable side effects are similar to arsenic poisoning. Among clinicians, it is colloquially referred to as "arsenic in antifreeze". Severe and life-threatening adverse reactions are associated with<unk> . It is known to cause a range of side effects including convulsions, fever, loss of consciousness, rashes, bloody stools, nausea and vomiting. In approximately 5-10% of cases, it causes encephalopathy. Of those, about 50% die due to encephalopathy-related adverse reactions. Additional potentially serious side effects of<unk>  include damage to the heart, presence of albumin in the urine that could be associated with kidney damage, and an increase in blood pressure. Cautions Numerous warnings must be examined before<unk>  treatment can be initiated. Prior to initiation, the following must be noted: glucose-6-phosphate dehydrogenase deficiency, kidney or liver disease, cardiac problems (high blood pressure, irregular beating of the heart or arrhythmias, any damage to the heart muscles and potential signs of heart failure), preexisting nervous system disorders, and any signs of leprosy. Routine laboratory testing is needed before and after<unk>  initiation. Laboratory parameters for both therapeutic effects and toxic effects need to be evaluated. Blood analysis is used to detect the presence of trypanosomes. An evaluation of the cerebrospinal fluid via a lumbar puncture is also used to determine an individual's white blood count and level of protein. These are diagnostic criteria such that the presence of trypanosomes, an elevated white blood count greater than five per microliter, or a protein content greater than 40 mg are considered abnormal and initiation should be considered. Continuous cerebrospinal fluid evaluation should be repeated every six months for at least three years in individuals that have undergone<unk>  treatment. To assess potential concerns related to toxicity, the following should be completed: a complete blood count, an assessment of electrolyte levels, liver and kidney function tests, and a urinalysis to detect the appearance, concentration and content of the urine.<unk>  should be given using glass syringes (if they can be reliably sterilized). The propylene glycol it contains is capable of dissolving plastic. Pregnancy and breastfeeding Currently,<unk>  is not recommended for use in pregnant women. The World Health Organization suggests that treatment be deferred until immediately after delivery since the effects of the medication on the developing fetus have not yet been established. Lactation guidelines associated with<unk>  have not yet been established.
Melarsoprol
Trenbolone hexahydrobenzylcarbonate
Prosultiamine
Fursultiamine
Artemether
Quinine
Dimetacrine
Boron trichloride